Extrapyramidal side effects of neuroleptic and antidepressant treatment: Assessment of potential risk factors through CYP2D6 genetic polymorphism;Effets indesirables extrapyramidaux des neuroleptiques et antidepresseurs - Recherche de facteurs de risque: Role du polymorphisme genetique du CYP2D6

Encephale

Volumn 26, Issue 1, 2000, Pages 62-67

  Reggiani, K ^a   Vandel, P ^b   Haffen, E ^b   Sechter, D ^b   Bizouard, P ^b   Vandel, S ^b  

^a Service des Enfants   (France)

^b NONE

Author keywords

Antidepressant; Antipsychotic; CYP2D6 phenotype; Extrapyramidal side effects; Predisposing factor

Indexed keywords

ALIMEMAZINE; AMISULPRIDE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYAMEMAZINE; CYTOCHROME P450; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DOPAMINE; FLUOXETINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; LOXAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; PAROXETINE; PENFLURIDOL; PERICIAZINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; UNCLASSIFIED DRUG; VALPROMIDE; VENLAFAXINE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG INDUCED DISEASE; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENETIC POLYMORPHISM; HUMAN; MALE; MENTAL DISEASE; PHENOTYPE; PSYCHOSIS; RISK FACTOR; ADOLESCENT; BRAIN; CHEMICALLY INDUCED DISORDER; EXTRAPYRAMIDAL SYNDROME; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PHYSIOLOGY;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRAIN; CYTOCHROME P-450 CYP2D6; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0034007646     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. ALVAN G, BECHTEL P, ISELIUS L et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990 ; 39 : 533-7.
2. ARTHUR H, DAHL ML, SIWERS BO et al. Polymorphic drug meta bolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995 ; 15 : 211-6.
3. ARYA DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994 ; 165 : 728-33.
4. AWAD AG. Quality of life of schizophrenic patients on medication for new drug trials. Hosp Commun Psychiatry 1992 ; 43 : 262-5.
5. AWAD AG, HOGAN TP. Subjective response to neuroleptics and the quality of life : implications for treatment outcome. Acta Psychiatr Scand 1994 ; 89 (Suppl 380) : 27-32.
6. BARBEAU A, ROY M, PARIS S et al. Ecogenetics of Parkinson's disease : 4-hydroxylation of debrisoquine. Lancet 1985 ; 30 : 1213-6.
7. BAUMANN P, JONZIER-PEREY M. GC and GC-MS procedure for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chim Acta 1988 ; 171 : 211-22.
8. CASEY DE, KEEPERS GA. Neuroleptic side-effects : acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol Curr Trends 1988 ; 5 : 74-93.
9. DAHL ML, BERTILSSON L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1992 ; 3: 61-70.
10. DERENNE F, JOANNE C, VANDEL S et al. Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 1989 ; 36 : 53-8.
11. FLEISCHHACKER WW, MEISE U, GUNTHER V et al. Compliance with antipsychotic drug treatment : influence of side-effects. Acta Psychiatr Scand 1994 ; 89 (Suppl 382) : 11-5.
12. GARDOS G, CASEY DE, COLE JO et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatr 1994 ; 151 : 836-41.
13. GERBER PE, LYND LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998 ; 32 : 692-8
14. HILDEBRAND M, SEIFERT W, REICHENBERGER A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 1989 ; 36 : 315-8.
15. KALOW W, TYNDALE RF. Debrisoquine/sparteine monooxygenase and other P-450s in brain. In: Kalow W, ed. Pharmacogenetics of drug metabolism. New York : Pergamon Press Inc. 1992 ; 649-56.
16. KANE JM. Schizophrenia. N Engl J Med 1996 ; 334 : 34-41.
17. KEKS NA. Minimizing the non extra-pyramidal side-effects of antipsychotics. Acta Psychiatr Scand 1996 ; 94 : 18-24.
18. LEO RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996 ; 57 : 449-54.
19. MARSDEN CD, JENNER P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980 ; 10 : 55-72.
20. MILLER LG, JANKOVIC J. Drug-induced movement disorders : an overview. In : A Joseph, R Young, eds. Movements disorders in neurology and neuropsychiatry. Boston: Blackwell Scientific, 1992 : 5-32.
21. MYRIANTHOPOULOS N, KURLAND AA, KURLAND LT. Hereditary predisposition in drug-induced parkinsonism. Arch Neurol 1962 ; 6 : 19-23.
22. NEMEROFF CB, DEVANE CL, POLLOCK BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatr 1996 ; 153 (3) : 311-20.
23. 3H]GBR-12935 binding proteins. Arch Biochem Biophys 1990 ; 276 : 424-32.
24. PRICE EVANS DA, MAHGOUB A, SLOAN TP et al. A family and population study of the genetic polymorphism of drug oxidation in white british population. J Med Genet 1980 ; 17 : 102-5.
25. RICHARDSON M, HAUGLAND G, CRAIG T. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatr 1991 ; 148 : 1322-8.
26. RUPP A, KEITH SJ. The costs of schizophrenia. Psychiatric Clin N Am 1993 ; 16 : 413-23.
27. SACHDEV P, KRUK J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994 ; 51 : 963-74.
28. SCHMID B, BIRCHER J, PREISIG R et al. Polymorphic dextromethorphan metabolism. Co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985 ; 38 : 618-24.
29. SPINA E, ANCIONE M, DI ROSSA AE et al. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 1992 ; 42 : 347-8.
30. STEIGER MJ, LLEDO P, QUINN NP et al. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992 ; 86 : 159-64.
31. STEINER E, BERTILSSON L, SAWE J et al. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988 ; 44 : 431-5.
32. STEINER E, ISELIUS L, ALVAN G et al. A family study of genetic and environnemental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 1985 ; 38 : 394-401.
33. TU JB. Psychopharmacogenetic basis of medication-induced movement disorders. Int Clin Psychopharmacol 1997 ; 12 : 1-12.
34. VACCARO JV, YOUNG AS, GLYNN S. Community-based care of individuals with schizophrenia. Psychiatric Clin N Am 1993 ; 16 : 387-99.
35. VANDEL P, BONIN B, LEVEQUE E et al. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997 ; 7 : 207-12.
36. VANDEL P, BONIN B, VANDEL S et al. CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects. Med Hypotheses 1996 ; 47 : 439-42.